Análisis Argos
COO
COOCara
The Cooper Companies, Inc. · Healthcare
US$ 74.20
precio al 2026-07-04
Valor justo Argos*
US$ 30–33
vs. su valor justo
125% por encima
Score Argos
36/100
LA RESPUESTA
El mercado le pide crezca 38.8% al año — más de lo que ha demostrado (4.7%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO3/6PASADO2/6SALUD3/6DIVIDENDO3/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO2/6SALUD3/6DIVIDENDO3/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance razonable
DividendoRetorno al accionista moderado
Score Argos36de 100Cara
Ingresos5%
US$ 4.1 B
Margen operativo8%
16.7%
Flujo de caja libre48%
US$ 0.4 B
Deuda neta
US$ 2.7 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 14.5B
P/E38.6x
EV/EBITDA15.5x
FCF yield3%
ROIC4.1%
Margen operativo16.7%
Crecim. ingresos+5.1%/año
Piotroski F5/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

fool.com · 23 jun
SoundHound AI's COO Sells 65K Shares
The COO sold 64,994 shares, representing a transaction value of approximately ~$485,000. This sale accounted for 3.7% of Michael Zagorsek's equity holdings.
zacks.com · 23 jun
Here's Why The Cooper Companies (COO) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
gurufocus.com · 13 jun
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
cnbc.com · 12 jun
SpaceX COO Shotwell says Tesla tie-up ‘might make Elon's life a little easier'
SpaceX's COO Gwynne Shotwell didn't dismiss the possibility of a tie-up with Tesla, Elon Musk's other trillion-dollar public company. A tie-up "might make Elon's life a little easier," Shotwell told CNBC, as SpaceX was preparing to hit the Nasdaq following the largest IPO on record.
zacks.com · 9 jun
Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
seekingalpha.com · 9 jun
The Cooper Companies: I Can See A Potential Upgrade On The Horizon
The Cooper Companies, Inc. remains a Hold as valuation nears attractive levels but litigation risk and mixed profitability warrant caution. Revenue growth is robust, particularly in the CooperVision segment, with strong performance in EMEA and the Americas offsetting Asia Pacific softness. Litigation charges from embryo culture media recalls have materially impacted reported profitability, but are not expected to alter COO's long-term outlook.
fool.com · 8 jun
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing
Whitehead sold 3,901 shares for a total transaction value of approximately ~$828K on June 3, 2026. This sale represented 27.37% of Whitehead's direct holdings prior to the transaction, reducing his direct position to 10,351 shares.
zacks.com · 8 jun
The Cooper Companies (COO) Reliance on International Sales: What Investors Need to Know
Evaluate The Cooper Companies' (COO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.